Drug Approval | June 22, 2024
Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
Berlinger brings a suite of proprietary and high-quality hardware and software solutions that broaden Sensitech's end-to-end cold chain monitoring product portfolio
This clearance is a foundational step in Roche's commitment to enable routine clinical diagnosis with its digital pathology solutions
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
Subscribe To Our Newsletter & Stay Updated
